TELA Bio (TELA) Expected to Announce Quarterly Earnings on Monday

Key Points

• TELA Bio is expected to announce its Q2 2025 earnings on August 11, with analysts predicting an earnings loss of ($0.18) per share and revenue of $20.67 million.
• In its previous earnings report, TELA Bio missed analyst expectations, reporting an EPS of ($0.25) and revenue of $18.52 million.
• Wall Street analysts recently downgraded TELA Bio to a "sell" rating, with a consensus price target of $7.25 and mixed opinions from five analysts on the stock's rating.

TELA Bio (NASDAQ:TELA - Get Free Report) is anticipated to announce its Q2 2025 earnings results after the market closes on Monday, August 11th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $20.67 million for the quarter.

TELA Bio (NASDAQ:TELA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.04). The firm had revenue of $18.52 million for the quarter, compared to analysts' expectations of $17.35 million. TELA Bio had a negative return on equity of 402.45% and a negative net margin of 61.00%. On average, analysts expect TELA Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TELA Bio Trading Up 2.2%

Shares of NASDAQ TELA traded up $0.04 during midday trading on Monday, reaching $1.90. 2,211 shares of the stock were exchanged, compared to its average volume of 181,921. The company has a market capitalization of $75.15 million, a P/E ratio of -1.35 and a beta of 0.93. TELA Bio has a 52-week low of $0.86 and a 52-week high of $4.30. The company has a current ratio of 4.22, a quick ratio of 3.40 and a debt-to-equity ratio of 2.28. The stock has a 50 day moving average price of $1.83 and a 200-day moving average price of $1.81.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut shares of TELA Bio from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, TELA Bio presently has a consensus rating of "Hold" and a consensus price target of $7.25.

About TELA Bio

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.